Amrut Ambardekar
Concepts (438)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart-Assist Devices | 39 | 2026 | 562 | 8.030 |
Why?
| | Heart Failure | 55 | 2026 | 2175 | 6.150 |
Why?
| | Heart Transplantation | 25 | 2025 | 733 | 4.690 |
Why?
| | Cardiomyopathies | 15 | 2026 | 333 | 3.280 |
Why?
| | Amyloid Neuropathies, Familial | 8 | 2026 | 23 | 2.550 |
Why?
| | Amyloidosis | 4 | 2023 | 45 | 1.700 |
Why?
| | Heart Ventricles | 9 | 2020 | 754 | 1.530 |
Why?
| | Prealbumin | 8 | 2026 | 36 | 1.510 |
Why?
| | Cardiomyopathy, Dilated | 9 | 2020 | 358 | 1.060 |
Why?
| | Myocardium | 11 | 2026 | 946 | 1.050 |
Why?
| | Myocytes, Cardiac | 14 | 2026 | 551 | 1.010 |
Why?
| | Ventricular Dysfunction, Left | 8 | 2023 | 373 | 1.010 |
Why?
| | Cardiomyopathy, Hypertrophic | 2 | 2024 | 145 | 0.920 |
Why?
| | Humans | 111 | 2026 | 143822 | 0.830 |
Why?
| | Arrhythmias, Cardiac | 6 | 2022 | 351 | 0.800 |
Why?
| | Ventricular Dysfunction, Right | 3 | 2020 | 245 | 0.780 |
Why?
| | Defibrillators, Implantable | 4 | 2020 | 315 | 0.770 |
Why?
| | Graft Rejection | 4 | 2025 | 536 | 0.760 |
Why?
| | Rejuvenation | 1 | 2022 | 19 | 0.740 |
Why?
| | Assisted Circulation | 2 | 2021 | 25 | 0.730 |
Why?
| | Aortic Valve Insufficiency | 1 | 2022 | 44 | 0.720 |
Why?
| | Fibrosis | 5 | 2022 | 547 | 0.710 |
Why?
| | Transplant Recipients | 4 | 2021 | 180 | 0.700 |
Why?
| | Echocardiography | 7 | 2017 | 642 | 0.700 |
Why?
| | Vascular Stiffness | 2 | 2017 | 462 | 0.690 |
Why?
| | Stroke Volume | 9 | 2024 | 617 | 0.680 |
Why?
| | Hemodynamics | 7 | 2023 | 1116 | 0.680 |
Why?
| | Calcineurin Inhibitors | 1 | 2021 | 69 | 0.660 |
Why?
| | Giant Cells | 1 | 2020 | 22 | 0.660 |
Why?
| | Middle Aged | 42 | 2026 | 35631 | 0.660 |
Why?
| | Arteries | 1 | 2022 | 259 | 0.650 |
Why?
| | Immunosuppressive Agents | 5 | 2021 | 843 | 0.640 |
Why?
| | Aortic Diseases | 1 | 2021 | 123 | 0.630 |
Why?
| | Heart Neoplasms | 1 | 2020 | 55 | 0.630 |
Why?
| | Ventricular Function, Left | 7 | 2023 | 522 | 0.630 |
Why?
| | Sarcoma, Kaposi | 1 | 2020 | 83 | 0.620 |
Why?
| | Myocarditis | 1 | 2020 | 102 | 0.600 |
Why?
| | Ventricular Remodeling | 5 | 2026 | 274 | 0.600 |
Why?
| | Coronary Vessels | 2 | 2018 | 250 | 0.600 |
Why?
| | Male | 56 | 2026 | 71570 | 0.590 |
Why?
| | Ventricular Function, Right | 4 | 2020 | 296 | 0.580 |
Why?
| | Myocardial Contraction | 4 | 2020 | 299 | 0.570 |
Why?
| | Brugada Syndrome | 2 | 2009 | 14 | 0.560 |
Why?
| | Heart | 6 | 2023 | 633 | 0.540 |
Why?
| | Female | 54 | 2026 | 77571 | 0.530 |
Why?
| | Aged | 28 | 2026 | 25616 | 0.520 |
Why?
| | Bariatric Surgery | 1 | 2021 | 232 | 0.520 |
Why?
| | Extracellular Matrix | 1 | 2021 | 563 | 0.520 |
Why?
| | Treatment Outcome | 16 | 2026 | 11460 | 0.500 |
Why?
| | Myocardial Ischemia | 4 | 2019 | 278 | 0.490 |
Why?
| | Cryosurgery | 1 | 2016 | 47 | 0.460 |
Why?
| | Heart Rate | 2 | 2021 | 843 | 0.450 |
Why?
| | Thrombosis | 2 | 2016 | 393 | 0.440 |
Why?
| | Benzoic Acid | 4 | 2026 | 9 | 0.420 |
Why?
| | Tachycardia, Ventricular | 1 | 2016 | 177 | 0.420 |
Why?
| | Surgical Procedures, Operative | 1 | 2017 | 266 | 0.420 |
Why?
| | Blood Pressure | 5 | 2022 | 1751 | 0.410 |
Why?
| | Electrocardiography | 4 | 2020 | 635 | 0.400 |
Why?
| | Marijuana Abuse | 1 | 2016 | 211 | 0.400 |
Why?
| | Aorta, Thoracic | 1 | 2015 | 288 | 0.370 |
Why?
| | Myofibrils | 3 | 2022 | 49 | 0.370 |
Why?
| | Physician-Patient Relations | 1 | 2017 | 585 | 0.370 |
Why?
| | Patient-Centered Care | 2 | 2021 | 542 | 0.360 |
Why?
| | Alternative Splicing | 2 | 2026 | 243 | 0.360 |
Why?
| | Recovery of Function | 3 | 2026 | 695 | 0.360 |
Why?
| | Adult | 23 | 2026 | 40130 | 0.340 |
Why?
| | Guideline Adherence | 3 | 2011 | 563 | 0.340 |
Why?
| | Cardiology | 2 | 2023 | 287 | 0.320 |
Why?
| | Patient Compliance | 2 | 2017 | 612 | 0.320 |
Why?
| | Pyrazoles | 4 | 2026 | 499 | 0.320 |
Why?
| | Cardiac Tamponade | 1 | 2010 | 14 | 0.310 |
Why?
| | Calcium | 4 | 2023 | 1181 | 0.310 |
Why?
| | RNA, Long Noncoding | 2 | 2022 | 177 | 0.310 |
Why?
| | Risk Assessment | 6 | 2021 | 3556 | 0.300 |
Why?
| | Baroreflex | 2 | 2021 | 56 | 0.300 |
Why?
| | Sarcomeres | 3 | 2022 | 99 | 0.300 |
Why?
| | Hospitals, Rural | 1 | 2009 | 44 | 0.300 |
Why?
| | Cardiac Output | 3 | 2023 | 179 | 0.300 |
Why?
| | Electric Stimulation Therapy | 1 | 2010 | 80 | 0.300 |
Why?
| | Safety | 1 | 2011 | 352 | 0.290 |
Why?
| | Cardiac Pacing, Artificial | 1 | 2009 | 82 | 0.290 |
Why?
| | Hospitals, Urban | 1 | 2009 | 137 | 0.290 |
Why?
| | Automobile Driving | 1 | 2011 | 153 | 0.290 |
Why?
| | Cannabis | 1 | 2016 | 517 | 0.290 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2590 | 0.290 |
Why?
| | Pulsatile Flow | 2 | 2018 | 55 | 0.280 |
Why?
| | Mastitis | 1 | 2007 | 6 | 0.270 |
Why?
| | Registries | 6 | 2021 | 2242 | 0.270 |
Why?
| | Counseling | 1 | 2011 | 400 | 0.270 |
Why?
| | Vascular Remodeling | 2 | 2021 | 203 | 0.270 |
Why?
| | Mineralocorticoid Receptor Antagonists | 2 | 2023 | 56 | 0.270 |
Why?
| | Antiviral Agents | 2 | 2025 | 743 | 0.270 |
Why?
| | Diagnosis, Differential | 4 | 2019 | 1502 | 0.260 |
Why?
| | Puerperal Disorders | 1 | 2007 | 36 | 0.260 |
Why?
| | Quality Assurance, Health Care | 1 | 2009 | 314 | 0.260 |
Why?
| | Follow-Up Studies | 7 | 2025 | 5317 | 0.260 |
Why?
| | Coronary Disease | 1 | 2009 | 369 | 0.260 |
Why?
| | Cytomegalovirus | 2 | 2025 | 168 | 0.260 |
Why?
| | Environment | 1 | 2009 | 306 | 0.250 |
Why?
| | Length of Stay | 2 | 2009 | 1312 | 0.250 |
Why?
| | Retrospective Studies | 14 | 2025 | 16755 | 0.250 |
Why?
| | Prospective Studies | 10 | 2021 | 7900 | 0.240 |
Why?
| | Diastole | 2 | 2018 | 141 | 0.240 |
Why?
| | Troponin I | 2 | 2019 | 81 | 0.230 |
Why?
| | HIV Infections | 1 | 2020 | 3048 | 0.230 |
Why?
| | Diabetic Cardiomyopathies | 1 | 2025 | 34 | 0.220 |
Why?
| | Inpatients | 1 | 2009 | 528 | 0.220 |
Why?
| | Heart Failure, Systolic | 2 | 2024 | 27 | 0.220 |
Why?
| | Quality of Health Care | 1 | 2009 | 649 | 0.220 |
Why?
| | Methyltransferases | 1 | 2025 | 74 | 0.220 |
Why?
| | Biomarkers | 4 | 2026 | 4248 | 0.210 |
Why?
| | Double-Blind Method | 2 | 2026 | 2017 | 0.210 |
Why?
| | Cytomegalovirus Infections | 1 | 2025 | 205 | 0.200 |
Why?
| | Cyclic Nucleotide Phosphodiesterases, Type 3 | 1 | 2023 | 8 | 0.200 |
Why?
| | Prognosis | 6 | 2025 | 4211 | 0.200 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2026 | 195 | 0.200 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2023 | 33 | 0.200 |
Why?
| | Quality of Life | 6 | 2024 | 3142 | 0.190 |
Why?
| | Polymorphism, Single Nucleotide | 3 | 2021 | 2167 | 0.190 |
Why?
| | MicroRNAs | 2 | 2022 | 699 | 0.190 |
Why?
| | Perioperative Care | 2 | 2017 | 223 | 0.190 |
Why?
| | Physical Conditioning, Animal | 1 | 2025 | 248 | 0.190 |
Why?
| | Heart Injuries | 1 | 2023 | 41 | 0.190 |
Why?
| | Practice Guidelines as Topic | 3 | 2025 | 1525 | 0.190 |
Why?
| | Mitochondrial Membrane Transport Proteins | 1 | 2022 | 46 | 0.190 |
Why?
| | Preoperative Care | 2 | 2017 | 376 | 0.190 |
Why?
| | Metalloproteases | 1 | 2022 | 41 | 0.180 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2023 | 105 | 0.180 |
Why?
| | Patient Transfer | 2 | 2019 | 197 | 0.180 |
Why?
| | Cadherin Related Proteins | 1 | 2022 | 12 | 0.180 |
Why?
| | Sequence Analysis, RNA | 2 | 2021 | 445 | 0.180 |
Why?
| | Matrix Metalloproteinases, Secreted | 1 | 2021 | 12 | 0.180 |
Why?
| | Long Term Adverse Effects | 1 | 2021 | 12 | 0.180 |
Why?
| | ADAMTS4 Protein | 1 | 2021 | 16 | 0.180 |
Why?
| | Cohort Studies | 6 | 2023 | 5862 | 0.180 |
Why?
| | Succinic Acid | 2 | 2019 | 42 | 0.180 |
Why?
| | Hospitalization | 4 | 2024 | 2340 | 0.180 |
Why?
| | Triage | 1 | 2024 | 247 | 0.180 |
Why?
| | Cation Transport Proteins | 1 | 2022 | 117 | 0.170 |
Why?
| | Recurrence | 2 | 2025 | 1122 | 0.170 |
Why?
| | Leukopenia | 1 | 2021 | 33 | 0.170 |
Why?
| | Hepatocyte Nuclear Factor 1-alpha | 1 | 2021 | 22 | 0.170 |
Why?
| | Cardiovascular System | 1 | 2023 | 140 | 0.170 |
Why?
| | Calcium-Binding Proteins | 1 | 2022 | 220 | 0.170 |
Why?
| | Pressoreceptors | 1 | 2021 | 19 | 0.170 |
Why?
| | Carrier Proteins | 2 | 2022 | 750 | 0.170 |
Why?
| | Mice | 13 | 2025 | 18421 | 0.170 |
Why?
| | Hypertension | 2 | 2020 | 1239 | 0.160 |
Why?
| | Mycophenolic Acid | 1 | 2021 | 120 | 0.160 |
Why?
| | Muscle Proteins | 1 | 2022 | 247 | 0.160 |
Why?
| | Case-Control Studies | 4 | 2022 | 3614 | 0.160 |
Why?
| | Myocardial Infarction | 2 | 2023 | 1084 | 0.160 |
Why?
| | Cell Adhesion | 2 | 2018 | 457 | 0.160 |
Why?
| | Epigenesis, Genetic | 1 | 2025 | 684 | 0.160 |
Why?
| | Immunohistochemistry | 2 | 2021 | 1733 | 0.160 |
Why?
| | Transcriptome | 3 | 2025 | 1047 | 0.150 |
Why?
| | Animals | 17 | 2026 | 38140 | 0.150 |
Why?
| | HIV | 1 | 2020 | 248 | 0.150 |
Why?
| | Myocardial Reperfusion Injury | 1 | 2020 | 139 | 0.150 |
Why?
| | Disease Progression | 2 | 2018 | 2871 | 0.150 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2021 | 295 | 0.140 |
Why?
| | Severity of Illness Index | 5 | 2021 | 2926 | 0.140 |
Why?
| | Aortic Valve | 1 | 2022 | 360 | 0.140 |
Why?
| | Terminology as Topic | 1 | 2020 | 254 | 0.140 |
Why?
| | Exercise Test | 4 | 2023 | 621 | 0.140 |
Why?
| | Cell Culture Techniques | 1 | 2021 | 379 | 0.140 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2020 | 187 | 0.140 |
Why?
| | United States | 9 | 2023 | 15602 | 0.140 |
Why?
| | Longitudinal Studies | 3 | 2016 | 2948 | 0.140 |
Why?
| | Clinical Decision-Making | 2 | 2020 | 345 | 0.140 |
Why?
| | Filamins | 1 | 2018 | 28 | 0.130 |
Why?
| | Rats | 6 | 2026 | 5609 | 0.130 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2018 | 188 | 0.130 |
Why?
| | Induced Pluripotent Stem Cells | 1 | 2021 | 276 | 0.130 |
Why?
| | Mitochondrial Proteins | 1 | 2019 | 255 | 0.130 |
Why?
| | NAV1.5 Voltage-Gated Sodium Channel | 1 | 2017 | 16 | 0.130 |
Why?
| | Immunity, Cellular | 1 | 2018 | 273 | 0.130 |
Why?
| | Mutation | 2 | 2018 | 4106 | 0.130 |
Why?
| | Caliciviridae Infections | 1 | 2016 | 18 | 0.130 |
Why?
| | ErbB Receptors | 1 | 2020 | 626 | 0.120 |
Why?
| | PTEN Phosphohydrolase | 1 | 2018 | 166 | 0.120 |
Why?
| | Down-Regulation | 2 | 2016 | 641 | 0.120 |
Why?
| | Pilot Projects | 3 | 2019 | 1851 | 0.120 |
Why?
| | Histone Deacetylases | 1 | 2018 | 210 | 0.120 |
Why?
| | Cerebrovascular Circulation | 1 | 2018 | 272 | 0.120 |
Why?
| | Brain | 2 | 2018 | 2901 | 0.120 |
Why?
| | Polypharmacy | 1 | 2017 | 85 | 0.120 |
Why?
| | Self Care | 1 | 2019 | 398 | 0.120 |
Why?
| | Transition to Adult Care | 1 | 2017 | 90 | 0.120 |
Why?
| | Time Factors | 5 | 2024 | 7068 | 0.120 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2018 | 264 | 0.120 |
Why?
| | Anesthetics | 1 | 2017 | 96 | 0.120 |
Why?
| | Eligibility Determination | 1 | 2016 | 69 | 0.120 |
Why?
| | Nonprescription Drugs | 1 | 2016 | 65 | 0.120 |
Why?
| | Receptors, Adrenergic, beta-1 | 1 | 2015 | 22 | 0.120 |
Why?
| | Drug Interactions | 1 | 2017 | 398 | 0.120 |
Why?
| | Prosthesis Design | 3 | 2014 | 354 | 0.120 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2016 | 93 | 0.120 |
Why?
| | Cell Differentiation | 2 | 2021 | 2045 | 0.120 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2020 | 541 | 0.120 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 1047 | 0.110 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2018 | 439 | 0.110 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 318 | 0.110 |
Why?
| | Phosphorylation | 3 | 2019 | 1761 | 0.110 |
Why?
| | Tacrolimus | 1 | 2016 | 197 | 0.110 |
Why?
| | Gene Expression Profiling | 2 | 2021 | 1817 | 0.110 |
Why?
| | Consensus | 3 | 2023 | 480 | 0.110 |
Why?
| | Postoperative Care | 1 | 2017 | 278 | 0.110 |
Why?
| | Hospital Mortality | 2 | 2009 | 975 | 0.110 |
Why?
| | Prescription Drugs | 1 | 2016 | 111 | 0.110 |
Why?
| | Viscosity | 1 | 2015 | 91 | 0.110 |
Why?
| | Partial Thromboplastin Time | 1 | 2014 | 52 | 0.110 |
Why?
| | Proportional Hazards Models | 3 | 2020 | 1305 | 0.110 |
Why?
| | Elastic Modulus | 1 | 2015 | 123 | 0.110 |
Why?
| | Cardiovascular Agents | 2 | 2020 | 158 | 0.110 |
Why?
| | Health Status | 1 | 2019 | 821 | 0.100 |
Why?
| | Attitude to Health | 1 | 2017 | 436 | 0.100 |
Why?
| | Atherosclerosis | 1 | 2018 | 401 | 0.100 |
Why?
| | Coronary Artery Disease | 1 | 2020 | 726 | 0.100 |
Why?
| | Risk Factors | 5 | 2025 | 10623 | 0.100 |
Why?
| | Systole | 1 | 2014 | 173 | 0.100 |
Why?
| | Hypoglycemic Agents | 1 | 2023 | 1393 | 0.100 |
Why?
| | Hip Prosthesis | 1 | 2014 | 46 | 0.100 |
Why?
| | Shock, Cardiogenic | 1 | 2014 | 60 | 0.100 |
Why?
| | Vaccination | 1 | 2022 | 1414 | 0.100 |
Why?
| | Cardiovascular Diseases | 1 | 2025 | 2098 | 0.100 |
Why?
| | Incidence | 3 | 2019 | 2845 | 0.100 |
Why?
| | Liver Transplantation | 1 | 2020 | 781 | 0.100 |
Why?
| | Transcription, Genetic | 1 | 2020 | 1504 | 0.100 |
Why?
| | Patient Selection | 2 | 2017 | 695 | 0.100 |
Why?
| | Postoperative Complications | 1 | 2025 | 2894 | 0.100 |
Why?
| | Prosthesis Failure | 1 | 2014 | 125 | 0.100 |
Why?
| | Ambulatory Care | 1 | 2017 | 592 | 0.100 |
Why?
| | Marijuana Smoking | 1 | 2016 | 257 | 0.090 |
Why?
| | Blood Coagulation | 1 | 2014 | 272 | 0.090 |
Why?
| | Quality Improvement | 1 | 2021 | 1268 | 0.090 |
Why?
| | Patient Education as Topic | 1 | 2017 | 791 | 0.090 |
Why?
| | Graft Survival | 2 | 2025 | 510 | 0.090 |
Why?
| | Ventricular Premature Complexes | 1 | 2012 | 36 | 0.090 |
Why?
| | Mice, Knockout | 3 | 2025 | 3120 | 0.090 |
Why?
| | Young Adult | 6 | 2019 | 13915 | 0.090 |
Why?
| | Natriuretic Peptides | 1 | 2011 | 8 | 0.090 |
Why?
| | Biopsy | 1 | 2015 | 1068 | 0.090 |
Why?
| | Aged, 80 and over | 4 | 2026 | 8130 | 0.080 |
Why?
| | Nuclear Proteins | 1 | 2016 | 751 | 0.080 |
Why?
| | Attitude of Health Personnel | 2 | 2017 | 1174 | 0.080 |
Why?
| | Reproducibility of Results | 2 | 2019 | 3392 | 0.080 |
Why?
| | Rats, Sprague-Dawley | 3 | 2026 | 2522 | 0.080 |
Why?
| | Neurotransmitter Agents | 1 | 2011 | 81 | 0.080 |
Why?
| | Receptors, Adrenergic, beta | 1 | 2011 | 61 | 0.080 |
Why?
| | Kaplan-Meier Estimate | 2 | 2010 | 957 | 0.080 |
Why?
| | Connectin | 2 | 2022 | 42 | 0.080 |
Why?
| | Gene Expression Regulation | 3 | 2020 | 2620 | 0.080 |
Why?
| | Endpoint Determination | 2 | 2020 | 82 | 0.080 |
Why?
| | Transforming Growth Factor beta1 | 2 | 2022 | 179 | 0.080 |
Why?
| | Decision Making | 1 | 2017 | 967 | 0.080 |
Why?
| | Task Performance and Analysis | 1 | 2011 | 196 | 0.080 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2011 | 193 | 0.080 |
Why?
| | Pericardial Effusion | 1 | 2010 | 20 | 0.080 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 1984 | 0.080 |
Why?
| | Stroke | 1 | 2019 | 1219 | 0.080 |
Why?
| | Heart Septum | 1 | 2009 | 28 | 0.080 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2011 | 225 | 0.080 |
Why?
| | Extracellular Matrix Proteins | 1 | 2011 | 157 | 0.080 |
Why?
| | DNA | 1 | 2016 | 1427 | 0.080 |
Why?
| | Comorbidity | 2 | 2020 | 1638 | 0.080 |
Why?
| | Myocardial Revascularization | 1 | 2009 | 75 | 0.080 |
Why?
| | Cells, Cultured | 3 | 2022 | 4172 | 0.070 |
Why?
| | Anticoagulants | 1 | 2014 | 718 | 0.070 |
Why?
| | Disease Management | 2 | 2025 | 639 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2017 | 1402 | 0.070 |
Why?
| | Exercise | 1 | 2020 | 2196 | 0.070 |
Why?
| | Ultrasonography | 1 | 2012 | 766 | 0.070 |
Why?
| | Europe | 2 | 2020 | 410 | 0.070 |
Why?
| | Disease Models, Animal | 4 | 2022 | 4553 | 0.070 |
Why?
| | Transcription Factors | 1 | 2016 | 1735 | 0.070 |
Why?
| | Coronary Circulation | 1 | 2008 | 135 | 0.070 |
Why?
| | Syndrome | 1 | 2008 | 373 | 0.070 |
Why?
| | Mice, Inbred C57BL | 3 | 2025 | 6032 | 0.060 |
Why?
| | Evidence-Based Medicine | 1 | 2011 | 711 | 0.060 |
Why?
| | Cardiac Catheterization | 2 | 2020 | 531 | 0.060 |
Why?
| | Blood Flow Velocity | 1 | 2008 | 414 | 0.060 |
Why?
| | Body Temperature | 1 | 2007 | 223 | 0.060 |
Why?
| | Continuity of Patient Care | 1 | 2009 | 286 | 0.060 |
Why?
| | Delivery of Health Care | 2 | 2023 | 946 | 0.060 |
Why?
| | Genetic Predisposition to Disease | 3 | 2020 | 2407 | 0.060 |
Why?
| | Survivors | 1 | 2009 | 513 | 0.060 |
Why?
| | Kidney Diseases | 1 | 2009 | 418 | 0.060 |
Why?
| | Clinical Protocols | 2 | 2017 | 280 | 0.060 |
Why?
| | Benzoxazoles | 1 | 2024 | 19 | 0.050 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2024 | 108 | 0.050 |
Why?
| | Education, Medical, Graduate | 1 | 2009 | 548 | 0.050 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2025 | 202 | 0.050 |
Why?
| | Genotype | 2 | 2020 | 1837 | 0.050 |
Why?
| | Sarcoplasmic Reticulum | 1 | 2023 | 43 | 0.050 |
Why?
| | Troponin | 1 | 2023 | 53 | 0.050 |
Why?
| | Cytokines | 1 | 2011 | 2093 | 0.050 |
Why?
| | Administration, Oral | 1 | 2025 | 841 | 0.050 |
Why?
| | Travel | 1 | 2023 | 136 | 0.050 |
Why?
| | Histone Deacetylase 6 | 1 | 2022 | 17 | 0.050 |
Why?
| | Disulfides | 1 | 2022 | 99 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2022 | 145 | 0.050 |
Why?
| | Catecholamines | 1 | 2022 | 89 | 0.050 |
Why?
| | Practice Patterns, Physicians' | 1 | 2011 | 1322 | 0.050 |
Why?
| | Echocardiography, Doppler, Color | 1 | 2002 | 37 | 0.050 |
Why?
| | Peptide Fragments | 1 | 2026 | 706 | 0.050 |
Why?
| | Up-Regulation | 1 | 2025 | 863 | 0.050 |
Why?
| | Cross-Sectional Studies | 3 | 2020 | 5761 | 0.050 |
Why?
| | Thiophenes | 1 | 2022 | 128 | 0.040 |
Why?
| | RNA Splicing Factors | 1 | 2022 | 63 | 0.040 |
Why?
| | Death, Sudden, Cardiac | 1 | 2023 | 196 | 0.040 |
Why?
| | Calcium Channels | 1 | 2022 | 155 | 0.040 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2022 | 321 | 0.040 |
Why?
| | Signal Transduction | 3 | 2021 | 5241 | 0.040 |
Why?
| | Valsalva Maneuver | 1 | 2021 | 10 | 0.040 |
Why?
| | Anaerobic Threshold | 1 | 2021 | 28 | 0.040 |
Why?
| | Signal Processing, Computer-Assisted | 1 | 2002 | 153 | 0.040 |
Why?
| | Phenylephrine | 1 | 2021 | 75 | 0.040 |
Why?
| | Adolescent | 4 | 2019 | 22234 | 0.040 |
Why?
| | Diagnostic Techniques, Cardiovascular | 1 | 2020 | 11 | 0.040 |
Why?
| | Pharmacogenomic Testing | 1 | 2021 | 62 | 0.040 |
Why?
| | Protein Isoforms | 1 | 2022 | 403 | 0.040 |
Why?
| | Prevalence | 2 | 2018 | 2819 | 0.040 |
Why?
| | Culture Media | 1 | 2021 | 160 | 0.040 |
Why?
| | Chronic Disease | 2 | 2017 | 1826 | 0.040 |
Why?
| | Cardiomegaly | 1 | 2022 | 172 | 0.040 |
Why?
| | Heart Valve Diseases | 1 | 2002 | 152 | 0.040 |
Why?
| | Survival Rate | 1 | 2025 | 2035 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2023 | 748 | 0.040 |
Why?
| | Heart Function Tests | 1 | 2020 | 55 | 0.040 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2021 | 141 | 0.040 |
Why?
| | Cardiac Resynchronization Therapy | 1 | 2020 | 45 | 0.040 |
Why?
| | Norepinephrine | 1 | 2021 | 193 | 0.040 |
Why?
| | Electric Countershock | 1 | 2020 | 116 | 0.040 |
Why?
| | Acylation | 1 | 2019 | 30 | 0.040 |
Why?
| | Adenosine Triphosphate | 1 | 2022 | 498 | 0.040 |
Why?
| | Seizures | 1 | 2023 | 454 | 0.040 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 1 | 2020 | 67 | 0.040 |
Why?
| | Fellowships and Scholarships | 1 | 2023 | 346 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2022 | 645 | 0.040 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2020 | 104 | 0.040 |
Why?
| | Program Evaluation | 2 | 2017 | 947 | 0.040 |
Why?
| | Principal Component Analysis | 1 | 2020 | 199 | 0.040 |
Why?
| | Gene Silencing | 1 | 2020 | 202 | 0.040 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2022 | 467 | 0.040 |
Why?
| | Methylation | 1 | 2019 | 243 | 0.040 |
Why?
| | Coronary Angiography | 1 | 2020 | 312 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2020 | 351 | 0.030 |
Why?
| | Mice, Knockout, ApoE | 1 | 2018 | 11 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2020 | 530 | 0.030 |
Why?
| | Pyridines | 1 | 2022 | 612 | 0.030 |
Why?
| | Internship and Residency | 1 | 2009 | 1245 | 0.030 |
Why?
| | Fatty Acids | 1 | 2021 | 450 | 0.030 |
Why?
| | Hydroxamic Acids | 1 | 2018 | 94 | 0.030 |
Why?
| | Oxygen Consumption | 1 | 2021 | 725 | 0.030 |
Why?
| | Hyperplasia | 1 | 2018 | 174 | 0.030 |
Why?
| | Myosins | 1 | 2018 | 138 | 0.030 |
Why?
| | Lysine | 1 | 2019 | 301 | 0.030 |
Why?
| | Zebrafish | 1 | 2022 | 524 | 0.030 |
Why?
| | Autoradiography | 1 | 2017 | 64 | 0.030 |
Why?
| | Fluorine Radioisotopes | 1 | 2017 | 13 | 0.030 |
Why?
| | Collagen | 1 | 2020 | 467 | 0.030 |
Why?
| | Diphenoxylate | 1 | 2016 | 5 | 0.030 |
Why?
| | Fibroblasts | 1 | 2022 | 1035 | 0.030 |
Why?
| | Alleles | 1 | 2020 | 883 | 0.030 |
Why?
| | Antidiarrheals | 1 | 2016 | 14 | 0.030 |
Why?
| | Loperamide | 1 | 2016 | 12 | 0.030 |
Why?
| | Atropine | 1 | 2016 | 36 | 0.030 |
Why?
| | Papio | 1 | 2017 | 92 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2018 | 408 | 0.030 |
Why?
| | Organ Culture Techniques | 1 | 2017 | 153 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2021 | 6004 | 0.030 |
Why?
| | Activities of Daily Living | 1 | 2020 | 435 | 0.030 |
Why?
| | Tissue Donors | 1 | 2019 | 413 | 0.030 |
Why?
| | Transcription Initiation Site | 1 | 2016 | 43 | 0.030 |
Why?
| | Transcription Elongation, Genetic | 1 | 2016 | 24 | 0.030 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 465 | 0.030 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2018 | 219 | 0.030 |
Why?
| | Gastrointestinal Agents | 1 | 2016 | 65 | 0.030 |
Why?
| | Radiopharmaceuticals | 1 | 2017 | 191 | 0.030 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2021 | 904 | 0.030 |
Why?
| | 3' Untranslated Regions | 1 | 2016 | 152 | 0.030 |
Why?
| | Acetylation | 1 | 2016 | 245 | 0.030 |
Why?
| | Actins | 1 | 2018 | 428 | 0.030 |
Why?
| | Drug Combinations | 1 | 2016 | 376 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2018 | 828 | 0.030 |
Why?
| | Circadian Rhythm | 1 | 2020 | 516 | 0.030 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2018 | 450 | 0.030 |
Why?
| | Cell Line | 1 | 2021 | 2906 | 0.030 |
Why?
| | Survival Analysis | 1 | 2018 | 1358 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2021 | 839 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2018 | 559 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2020 | 2097 | 0.030 |
Why?
| | Factor X | 1 | 2014 | 26 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2019 | 1065 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 2 | 2020 | 3834 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2020 | 2182 | 0.030 |
Why?
| | Self-Management | 1 | 2017 | 204 | 0.030 |
Why?
| | Mental Health | 1 | 2021 | 774 | 0.030 |
Why?
| | Cobalt | 1 | 2014 | 53 | 0.030 |
Why?
| | Polymerase Chain Reaction | 1 | 2016 | 1057 | 0.020 |
Why?
| | Reoperation | 1 | 2016 | 602 | 0.020 |
Why?
| | Action Potentials | 1 | 2017 | 508 | 0.020 |
Why?
| | Amino Acids, Aromatic | 1 | 2013 | 7 | 0.020 |
Why?
| | Warfarin | 1 | 2014 | 165 | 0.020 |
Why?
| | Models, Biological | 1 | 2021 | 1833 | 0.020 |
Why?
| | Self Report | 1 | 2017 | 865 | 0.020 |
Why?
| | Heparin | 1 | 2014 | 250 | 0.020 |
Why?
| | Medication Adherence | 1 | 2017 | 519 | 0.020 |
Why?
| | Creatine | 1 | 2013 | 63 | 0.020 |
Why?
| | RNA Polymerase II | 1 | 2016 | 349 | 0.020 |
Why?
| | Proteomics | 1 | 2019 | 1192 | 0.020 |
Why?
| | Mass Screening | 1 | 2021 | 1325 | 0.020 |
Why?
| | Glutamine | 1 | 2013 | 109 | 0.020 |
Why?
| | Child, Preschool | 2 | 2019 | 11631 | 0.020 |
Why?
| | Antibodies | 1 | 2014 | 399 | 0.020 |
Why?
| | Cell Cycle Proteins | 1 | 2016 | 636 | 0.020 |
Why?
| | Algorithms | 1 | 2020 | 1843 | 0.020 |
Why?
| | Alanine | 1 | 2013 | 168 | 0.020 |
Why?
| | Chromatin | 1 | 2016 | 554 | 0.020 |
Why?
| | Dyspnea | 1 | 2014 | 257 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2020 | 2847 | 0.020 |
Why?
| | Depression | 1 | 2021 | 1520 | 0.020 |
Why?
| | Fatigue | 1 | 2014 | 356 | 0.020 |
Why?
| | Lactic Acid | 1 | 2013 | 305 | 0.020 |
Why?
| | Phenotype | 1 | 2020 | 3183 | 0.020 |
Why?
| | Endothelium, Vascular | 1 | 2018 | 965 | 0.020 |
Why?
| | Patient Discharge | 1 | 2016 | 939 | 0.020 |
Why?
| | Sex Factors | 1 | 2015 | 2078 | 0.020 |
Why?
| | Catheter Ablation | 1 | 2012 | 351 | 0.020 |
Why?
| | Age Factors | 1 | 2015 | 3288 | 0.020 |
Why?
| | Glucose | 1 | 2013 | 1041 | 0.020 |
Why?
| | Child | 2 | 2019 | 22441 | 0.020 |
Why?
| | Focus Groups | 1 | 2009 | 573 | 0.010 |
Why?
| | Glomerular Filtration Rate | 1 | 2009 | 751 | 0.010 |
Why?
| | Infant | 1 | 2015 | 9886 | 0.010 |
Why?
| | Observer Variation | 1 | 2002 | 353 | 0.010 |
Why?
| | Clinical Competence | 1 | 2009 | 1226 | 0.010 |
Why?
|
|
Ambardekar's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|